NeuroFront

Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd, granting NeuroFront exclusive rights to develop, commercialize, and manufacture NRD.E1 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. In exchange, Novaremed will receive upfront and milestone payments totaling USD 130 million. Drug…